Literature DB >> 25259760

Electrooculography and optical coherence tomography reveal late-onset Best disease.

Ravie Makati1, Diana Shechtman, Eulogio Besada, Joseph J Pizzimenti.   

Abstract

PURPOSE: Best vitelliform macular dystrophy, also known as Best disease, is a macular dystrophy characterized by bilateral yellowish egg yolk-like lesion(s) present within the maculae. It is a slowly progressive disease that usually presents at childhood. Best vitelliform macular dystrophy frequently proceeds through stages, beginning with a classic presentation described as vitelliform. A similar condition, known as adult-onset foveomacular vitelliform dystrophy, has been described among adult patients. Although the two maculopathies may look similar, they are considered two separate entities, because of the age of onset and overall clinical presentation. CASE REPORT: A 54-year-old man presented with gradual-onset blurred near vision in each eye. Previous records showed a history of unremarkable dilated fundus examinations for the past 8 years. Best-corrected distance acuities measured 20/20 OD and 20/20 OS. Amsler grid testing revealed a mild metamorphopsia OD and OS. Dilated fundoscopy revealed macular pseudohypopyon in each eye. In vivo imaging of the maculae was obtained with spectral-domain optical coherence tomography findings. Electrooculography findings were consistent with Best vitelliform macular dystrophy of atypical, late onset.
CONCLUSIONS: Best vitelliform macular dystrophy may vary in its presentation. Electrooculography and spectral-domain optical coherence tomography can aid in establishing the definitive diagnosis.

Entities:  

Mesh:

Year:  2014        PMID: 25259760     DOI: 10.1097/OPX.0000000000000403

Source DB:  PubMed          Journal:  Optom Vis Sci        ISSN: 1040-5488            Impact factor:   1.973


  1 in total

1.  Multi-spectral imaging in adult-onset foveomacular vitelliform dystrophy: Report of two cases.

Authors:  Mingzhen Yuan; Feiyan Ma; Lulu Chen; Youxin Chen
Journal:  Am J Ophthalmol Case Rep       Date:  2022-04-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.